Patents Assigned to The Schepens Eye Research Institute, Inc.
  • Patent number: 10449234
    Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 22, 2019
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Sunil Chauhan, Reza Dana
  • Patent number: 10402985
    Abstract: In some implementations, there is provided a method. The method may include receiving data characterizing a plurality of digital video frames; detecting a plurality of features in each of the plurality of digital video frames; determining, from the detected features, a local scale change and a translational motion of one or more groups of features between at least a pair of the plurality of digital video frames; and calculating a likelihood of collision. Related apparatus, systems, techniques, and articles are also described.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 3, 2019
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Gang Luo, Eliezer Peli, Shrinivas Pundlik
  • Patent number: 10274503
    Abstract: The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularization. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: April 30, 2019
    Assignees: VEGENICS PTY LIMITED, THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
    Inventors: Megan E. Baldwin, Kameran Lashkari, Jie Ma
  • Publication number: 20190112610
    Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 18, 2019
    Applicant: The Schepens Eye Research Institute, Inc.
    Inventors: Patricia A. D'Amore, Magali Saint-Geniez, Cindy Park-Windhol
  • Publication number: 20190004064
    Abstract: The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.
    Type: Application
    Filed: July 11, 2018
    Publication date: January 3, 2019
    Applicants: The Schepens Eye Research Institute, Inc., Massachusetts Institute of Technology
    Inventors: Dong Feng Chen, Jianzhu Chen, Huihui Chen
  • Patent number: 10117906
    Abstract: The invention provides methods and compositions for minimizing, preventing, or treating damage to corneal nerves by administering to a subject with such damage or at risk of exposure to such damage a composition which blocks an activity of an IL-1 cytokine and/or an IL-17 cytokine.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: November 6, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Mohammad Dastjerdi, Sunil Chauhan
  • Patent number: 10105441
    Abstract: The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 23, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Mohammad Dastjerdi
  • Patent number: 10039790
    Abstract: The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: August 7, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Kameran Lashkari, Marie Shatos, Tat Fong Ng
  • Patent number: 10031346
    Abstract: In some example implementations, there is provided an apparatus. The apparatus may include a plurality of prism portions configured to shift light passing through the apparatus including the plurality of prisms portions, and a plurality of portions configured to pass light unshifted through the apparatus, wherein the apparatus combines the shifted light and the unshifted light passing through the apparatus. Related apparatus are also disclosed.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 24, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventor: Eliezer Peli
  • Patent number: 9986905
    Abstract: In some example implementations, there is provided a method for predicting retinal degeneration in multiple eye diseases. The method may include receiving three-dimensional data representative of a plurality of layers of a retina of a subject under test; determining, from the received data, oxygen concentration at one or more of the plurality of layers; detecting, based on the determined oxygen concentration, a region of at least one a high oxygen concentration in the retina or a low oxygen concentration in the retina; and comparing the detected region to reference data to determine whether the retina including the detected region suffers from or will suffer from at least one of a retinal disease or a degeneration of the retina. Related apparatus are also disclosed.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: June 5, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Kevin McHugh, Magali Saint-Geniez, Leo Kim
  • Patent number: 9883793
    Abstract: In some example implementations, there is provided a method. The method may include determining a probabilistic model representing threshold sensitivities across the visual field, the probabilistic model determined based on the data, the connection strengths, and the noise values. Related systems, methods, and articles of manufacture are also disclosed. In some implementations, the probabilistic model may include a continuous probability distribution.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: February 6, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Philipp Benner, Tobias Elze, Peter Bex
  • Patent number: 9872901
    Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: January 23, 2018
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan
  • Patent number: 9734586
    Abstract: In some implementations, there is provided a method. The method may include receiving data characterizing a plurality of digital video frames; detecting a plurality of features in each of the plurality of digital video frames; determining, from the detected features, a local scale change and a translational motion of one or more groups of features between at least a pair of the plurality of digital video frames; and calculating a likelihood of collision. Related apparatus, systems, techniques, and articles are also described.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: August 15, 2017
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Gang Luo, Eliezer Peli, Shrinivas Pundlik
  • Patent number: 9700201
    Abstract: Data is received characterizing a result of a first visual sensitivity test assessing capacity to detect spatial form across one or more different target sizes, and different contrasts. Using the received data, one or more first parameters defining a first estimated visual sensitivity for a first range of contrasts and a second range of spatial frequencies is determined. One or more second parameters defining a second estimated visual sensitivity for a third range of contrasts and a fourth range of spatial frequencies is determined using the one or more first parameters and a statistical inference by at least presenting a first visual stimulus, receiving a response, and determining a second visual stimulus based at least on the response and at least a rule. The one or more second parameters is provided. Related apparatus, systems, techniques and articles are also described.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: July 11, 2017
    Assignees: The Schepens Eye Research Institute, Inc., The Ohio State University
    Inventors: Peter Bex, Michael Dorr, Luis Lesmes, Zhong-Lin Lu
  • Patent number: 9623024
    Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: April 18, 2017
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventor: Andrius Kazlauskas
  • Patent number: 9365627
    Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory agent.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: June 14, 2016
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Patricia A. D'amore, Pablo Argüeso, Alisar S. Zahr
  • Patent number: 9309313
    Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: April 12, 2016
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan
  • Publication number: 20160022743
    Abstract: The present invention relates to use of very small embryonic-like (VSEL) stem cells in therapies for ocular disease involving retinal degeneration or dysfunction. The invention also included pharmaceutical compositions made with VSELs which may be used to restore lost vision or reduce or halt vision loss due to diseases or disorders of the retina, or other diseases or retinal injuries that would benefit from stem cell replacement therapy.
    Type: Application
    Filed: May 31, 2013
    Publication date: January 28, 2016
    Applicant: The Schepens Eye Research Institute, Inc.
    Inventors: Kameran LASHKARI, Michael YOUNG, Sarah EMINLI-MEISSNER, Wayne MARASCO, Robert PRETI
  • Patent number: 9061017
    Abstract: The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 23, 2015
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Kameran Lashkari, Marie Shatos, Tat Fong Ng
  • Publication number: 20150018267
    Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory Agent
    Type: Application
    Filed: August 6, 2012
    Publication date: January 15, 2015
    Applicant: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
    Inventors: Patricia A. D'Amore, Pablo Argüeso, Alisar S. Zahr